e-Health Intervention for Cancer of the Female Reproductive System

Recruiting in Palo Alto (17 mi)

Overseen byAnne Reb

Age: 18+

Sex: Female

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: City of Hope Medical Center

No Placebo Group

Trial Summary

What is the purpose of this trial?This trial studies how well the 'Day by Day' online program helps patients with advanced gynecologic cancer manage their fears about cancer progression. The program includes group sessions, self-study activities, and periodic updates to teach skills for reducing anxiety and worries.

Eligibility Criteria

This trial is for English-speaking women over 18 with stage III or IV gynecologic cancer (ovarian, endometrial, cervical, vulvar/vaginal), at least 3 months post-diagnosis. They must have significant fear of their cancer progressing as measured by a specific questionnaire. Those in hospice care, with severe depression, or unable to follow the study plan are excluded.

Inclusion Criteria

I am 18 years old or older.

My cancer is either improving or getting worse.

I am a woman diagnosed with advanced GYN cancer more than 3 months ago.

+2 more

Exclusion Criteria

You are currently receiving care in a hospice.

You have been diagnosed with severe depression using the Patient Health Questionnaire (PHQ-9).

Non-English speaking

+1 more

Participant Groups

The trial tests an e-health intervention called 'Day-by-Day' designed to manage fears about cancer progression in patients with advanced gynecologic cancers. It's based on the 'Conquer Fear' program and includes discussions, informational media interventions, questionnaires and telephone support to help reduce anxiety.

1Treatment groups

Experimental Treatment

Group I: Supportive Care (DBD)Experimental Treatment5 Interventions

Patients receive DBD intervention consisting of group and web-based self-study sessions and check-in calls on study. Patients also watch videos and receive handouts to reinforce the group sessions.